| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Chapter Links... |
 Cancer Drugs Fund List |
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
| 08.01.05 |
Platinum compounds |
|
|
| 08.01.05 |
Procarbazine |
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib
(tablet)
|
Formulary
|
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Axitinib
(tablet)
|
Formulary
|
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
|
Bosutinib
(tablet)
|
Formulary
|
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brigatinib (Alunbrig®)
(tablet)
|
Formulary
|
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
NICE TA670:Brigatinib for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (may be offered as an alternative to alectinib or crizotinib)
|
Cabozantinib (Cabometyx®)
(tablet)
|
Formulary
|
|
NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA516:Cabozantinib for treating medullary thyroid cancer
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Ceritinib
(capsule)
|
Formulary
|
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Crizotinib
(capsule)
|
Formulary
|
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Dacomitinib (Vizimpro®)
(film coated tablets)
|
Formulary
|
|
NICE TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Dasatinib
(tablet)
|
Formulary
|
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Erlotinib
(tablet)
|
Formulary
|
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Everolimus (Afinitor®)
(tablet)
|
Formulary
|
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus (Votubia®)
|
Formulary
|
For use as per commissioning criteria set by NHS England
|
|
|
Gefitinib
(tablet)
|
Formulary
|
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
Ibrutinib (Imbruvica®)
(tablets)
|
Formulary
|
|
NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA491:Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Imatinib
(tablet)
|
Formulary
|
|
NICE TA209:Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
|
Larotrectinib (Vitrakvi® )
(oral solution)
|
Formulary
|
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
|
Lorlatinib (Lorviqua®)
(tablet)
|
Formulary
|
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
|
Neratinib (Nerlynx®)
(tablets)
|
Formulary
|
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
|
Nilotinib
(capsule)
|
Formulary
|
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nintedanib
(capsule)
|
Formulary
|
Vargatef branf for NSCLC, Ofev brand for IPF in line with NICE guidance (see links)
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
|
Niraparib
(capsules)
|
Formulary
|
|
MHRA Advice Oct 2020: Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
|
Osimertinib
(tablet)
|
Formulary
|
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
|
Palbociclib (Ibrance®)
(capsules)
|
Formulary
|
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Pazopanib
(tablet)
|
Formulary
|
|
NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
|
Ponatinib
(tablet)
|
Formulary
|
|
NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Regorafenib (Stivarga® )
(tablet)
|
Formulary
|
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Ribociclib (Kisqali®)
(tablets)
|
Formulary
|
|
NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
|
Rucaparib (Rubraca®)
(tablets)
|
Formulary
|
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
|
Ruxolitinib (Jakavi®)
(tablet)
|
Formulary
|
 Commissioned by NHSE in line with NICE TA and treatment criteria detailed in Cancer Drugs Fund list or on Blueteq application forms.
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Sorafenib
(tablet)
|
Formulary
|
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib
(capsule)
|
Formulary
|
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Tivozanib
(capsules)
|
Formulary
|
|
NICE TA512:Tivozanib for treating advanced renal cell carcinoma
|
Trametinib
(tablet)
|
Formulary
|
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Vemurafenib
(tablet)
|
Formulary
|
|
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
|
Dabrafenib
(capsule)
|
Formulary
|
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
| 08.01.05 |
Taxanes |
|
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
| 08.01.05 |
Trabectedin |
|
|
| 08.01.05 |
Tretinoin |
|
|
| .... |
| Non Formulary Items |
Lapatinib (Tyverb®)
|
Non Formulary
|
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
|
Temsirolimus (Torisel®)
|
Non Formulary
|
|
NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
|
Vandetanib (Caprelsa®)
|
Non Formulary
|
|
|
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Traffic Light Status Information
| Status |
Description |
|
Suitable for prescribing by all in both primary and secondary care. |
|
Specialist recommended but suitable for continuation in primary care. |
|
Specialist initiated but suitable for continuation in primary care. |
|
Specialist initiated and for continuation in primary care under a locally approved shared care guideline. |
|
Suitable for prescribing in specialist settings (secondary care) only. |
|
Secondary care medicines to be used under specialised commissioning arrangements only. |
|
For primary care, either via FP10 or supplied through specialist services. These products may be stocked by hospital
pharmacies only for supply to primary care units/wards or for continuing supplies for patients admitted on therapy. |
|
Not recommended for use. |
|
|
|
